Media Releases
ANZUP’s TheraP trial has found that certain ‘spelling mistakes’ in prostate cancer DNA found in the blood can reveal hidden weaknesses that …
FIRST OF ITS KIND COMBINATION TREATMENT APPROACH IMPROVES SURVIVAL RATES IN AUSTRALIANS WITH METASTATIC PROSTATE CANCER New research findings were reported today …
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to …
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group …
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients …
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
This week the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) TheraP trial (ANZUP 1603) featured in The Lancet …
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) today announced interim results of their Phase 2 ENZA-p (ANZUP …
The Executive Officers’ Network (EON) is a collaboration between the fourteen Cancer Cooperative Trials Groups (CCTGs) that are supported by Cancer Australia
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and The George Institute for Global Health have announced a …
Groundbreaking work, through a series of cutting-edge clinical trials, being undertaken by two of the state’s leading cancer specialists, Louise Nott and …
New Clinical Trial for Personalised Adaptive Treatment of Prostate Cancer Enrolls First Participants
A randomised clinical trial aiming to improve survival in advanced prostate cancer by adapting treatment with a personalized dosing strategy has enrolled …
Dickon Hayne accepted the BJUI Global Prize for 2023 for the Pain-Free TRUS B article that featured in BJUI in 2022, at …
PSMA and FDG-PET as predictive and prognostic biomarkers TheraP biomarker Oct 2022 (1)Previously, results from the TheraP trial showed that treatment with …
This webinar was presented on May 18th, 2022 and involved two speakers’ presentations, followed by a panel discussion about Advances in the …
Research Review has provided a review of the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate (ANZUP) Cancer …
Listen to Associate Professor Niall Corcoran discuss if Triple Therapy for HSMPC is the New Standard of Care
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year follow up results of its TheraP (ANZUP …
The Australian-led clinical trial ENZAMET has shown that the addition of hormone therapy with a medicine called enzalutamide to standard therapy (ADT …
In this exclusive MedPage Today interview, Eric A. Klein, MD, discusses Enzalutamide’s impact on overall quality of life.